|
| | Publication Year | Title | Author(s) |
| 61 | Nov-2018 | Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database. | Salem, Mohamed E; Yin, Jun; Weinberg, Benjamin A; Renfro, Lindsay A; Pederson, Levi D; Maughan, Timothy S; Adams, Richard A; Van Cutsem, Eric; Falcone, Alfredo; Tebbutt, Niall C ; Seymour, Matthew T; Díaz-Rubio, Eduardo; Aranda, Enrique; Bokemeyer, Carsten; Heinemann, Volker; Wasan, Harpreet; de Gramont, Aimery; Grothey, Axel; Shi, Qian; Sargent, Daniel J; Marshall, John L |
| 62 | Oct-2018 | Targeted therapy for metastatic colorectal cancer. | Price, Timothy J; Tang, Monica; Gibbs, Peter; Haller, Daniel G; Peeters, Marc; Arnold, Dirk; Segelov, Eva; Roy, Amitesh; Tebbutt, Niall C ; Pavlakis, Nick; Karapetis, Chris; Burge, Matthew; Shapiro, Jeremy |
| 63 | 1-Jun-2018 | Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. | Sjoquist, Katrin M; Renfro, Lindsay A; Simes, R John; Tebbutt, Niall C ; Clarke, Stephen; Seymour, Matthew T; Adams, Richard A; Maughan, Timothy S; Saltz, Leonard; Goldberg, Richard M; Schmoll, Hans-Joachim; Van Cutsem, Eric; Douillard, Jean-Yves; Hoff, Paulo M; Hecht, Joel Randolph; Tournigand, Christophe; Punt, Cornelis J A; Koopman, Miriam; Hurwitz, Herbert; Heinemann, Volker; Falcone, Alfredo; Porschen, Rainer; Fuchs, Charles; Diaz-Rubio, Eduardo; Aranda, Enrique; Bokemeyer, Carsten; Souglakos, Ioannis; Kabbinavar, Fairooz F; Chibaudel, Benoist; Meyers, Jeffrey P; Sargent, Daniel J; de Gramont, Aimery; Zalcberg, John R |
| 64 | Apr-2018 | Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. | Tang, Monica; Price, Timothy Jay; Shapiro, Jeremy; Gibbs, Peter; Haller, Daniel G; Arnold, Dirk; Peeters, Marc; Segelov, Eva; Roy, Amitesh; Tebbutt, Niall C ; Pavlakis, Nick; Karapetis, Chris; Burge, Matthew |
| 65 | Apr-2018 | Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study. | Lau, David K ; Tay, Rebecca Y; Yeung, Yvonne H ; Chionh, Fiona; Mooi, Jennifer; Murone, Carmel ; Skrinos, Effie; Price, Timothy J; Mariadason, John M ; Tebbutt, Niall C |
| 66 | Apr-2018 | Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. | Elander, N O; Aughton, K; Ghaneh, P; Neoptolemos, J P; Palmer, D H; Cox, T F; Campbell, F; Costello, E; Halloran, C M; Mackey, J R; Scarfe, A G; Valle, J W; McDonald, A C; Carter, R; Tebbutt, Niall C ; Goldstein, D; Shannon, J; Dervenis, C; Glimelius, B; Deakin, M; Charnley, R M; Anthoney, Alan; Lerch, M M; Mayerle, J; Oláh, A; Büchler, M W; Greenhalf, W |
| 67 | 31-Jan-2018 | Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. | Jonker, Derek J; Nott, Louise; Yoshino, Takayuki; Gill, Sharlene; Shapiro, Jeremy; Ohtsu, Atsushi; Zalcberg, John; Vickers, Michael M; Wei, Alice C; Gao, Yuan; Tebbutt, Niall C ; Markman, Ben; Price, Timothy; Esaki, Taito; Koski, Sheryl; Hitron, Matthew; Li, Wei; Li, Youzhi; Magoski, Nadine M; Li, Chiang J; Simes, John; Tu, Dongsheng; O'Callaghan, Christopher J |
| 68 | 29-Jan-2018 | DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. | Tögel, Lars; Nightingale, Rebecca; Wu, Rui; Chüeh, Anderly C; Al-Obaidi, Sheren; Luk, Ian; Dávalos-Salas, Mercedes; Chionh, Fiona; Murone, Carmel ; Buchanan, Daniel D; Chatterton, Zac; Sieber, Oliver M; Arango, Diego; Tebbutt, Niall C ; Williams, David; Dhillon, Amardeep S; Mariadason, John M |
| 69 | 2018 | Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. | Elander, N O; Aughton, K; Ghaneh, P; Neoptolemos, J P; Palmer, D H; Cox, T F; Campbell, F; Costello, E; Halloran, C M; Mackey, J R; Scarfe, A G; Valle, J W; McDonald, A C; Carter, R; Tebbutt, Niall C ; Goldstein, D; Shannon, J; Dervenis, C; Glimelius, B; Deakin, M; Charnley, R M; Anthoney, A; Lerch, M M; Mayerle, J; Oláh, A; Büchler, M W; Greenhalf, W |
| 70 | 1-Dec-2017 | ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. | Pietrantonio, Filippo; Di Nicolantonio, Federica; Schrock, Alexa B; Lee, Jeeyun; Tejpar, Sabine; Sartore-Bianchi, Andrea; Hechtman, Jaclyn F; Christiansen, Jason; Novara, Luca; Tebbutt, Niall C ; Fucà, Giovanni; Antoniotti, Carlotta; Kim, Seung Tae; Murphy, Danielle; Berenato, Rosa; Morano, Federica; Sun, James; Min, Bosun; Stephens, Philip J; Chen, Marissa; Lazzari, Luca; Miller, Vincent A; Shoemaker, Robert; Amatu, Alessio; Milione, Massimo; Ross, Jeffrey S; Siena, Salvatore; Bardelli, Alberto; Ali, Siraj M; Falcone, Alfredo; de Braud, Filippo; Cremolini, Chiara |
| 71 | Nov-2017 | Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised,
double-blind, placebo-controlled, phase 3 trial. | Catenacci, Daniel V T; Tebbutt, Niall C ; Davidenko, Irina; Murad, André M; Al-Batran, Salah-Eddin; Ilson, David H; Tjulandin, Sergei; Gotovkin, Evengy; Karaszewska, Boguslawa; Bondarenko, Igor; Tejani, Mohamedtaki A; Udrea, Anghel A; Tehfe, Mustapha; De Vita, Ferdinando; Turkington, Cheryl; Tang, Rui; Ang, Agnes; Zhang, Yilong; Hoang, Tien; Sidhu, Roger; Cunningham, David |
| 72 | 30-Oct-2017 | SCORE: Shared care of Colorectal cancer survivors: protocol for a randomised controlled trial. | Jefford, Michael; Emery, Jon; Grunfeld, Eva; Martin, Andrew; Rodger, Paula; Murray, Alexandra M; De Abreu Lourenco, Richard; Heriot, Alexander; Phipps-Nelson, Jo; Guccione, Lisa; King, Dorothy; Lisy, Karolina; Tebbutt, Niall C ; Burgess, Adele N ; Faragher, Ian; Woods, Rodney; Schofield, Penelope |
| 73 | 24-Oct-2017 | The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. | Ghaneh, Paula; Kleeff, Jorg; Halloran, Christopher M; Raraty, Michael; Jackson, Richard; Melling, James; Jones, Owain; Palmer, Daniel H; Cox, Trevor F; Smith, Chloe J; O'Reilly, Derek A; Izbicki, Jakob R; Scarfe, Andrew G; Valle, Juan W; McDonald, Alexander C; Carter, Ross; Tebbutt, Niall C ; Goldstein, David; Padbury, Robert; Shannon, Jennifer; Dervenis, Christos; Glimelius, Bengt; Deakin, Mark; Anthoney, Alan; Lerch, Markus M; Mayerle, Julia; Oláh, Attila; Rawcliffe, Charlotte L; Campbell, Fiona; Strobel, Oliver; Büchler, Markus W; Neoptolemos, John P |
| 74 | Sep-2017 | K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. | Yeung, Yvonne; Lau, David K ; Chionh, Fiona; Tran, Hoanh; Tse, Janson W T; Weickhardt, Andrew J ; Nikfarjam, Mehrdad ; Scott, Andrew M ; Tebbutt, Niall C ; Mariadason, John M |
| 75 | 28-Jul-2017 | Oral versus intravenous fluoropyrimidines for colorectal cancer | Chionh, Fiona; Lau, David; Yeung, Yvonne; Price, Timothy; Tebbutt, Niall C |
| 76 | 10-Jun-2017 | Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. | Renfro, Lindsay A; Goldberg, Richard M; Grothey, Axel; Sobrero, Alberto; Adams, Richard A; Seymour, Matthew T; Heinemann, Volker; Schmoll, Hans-Joachim; Douillard, Jean-Yves; Hurwitz, Herbert; Fuchs, Charles S; Diaz-Rubio, Eduardo; Porschen, Rainer; Tournigand, Christophe; Chibaudel, Benoist; Hoff, Paulo M; Kabbinavar, Fairooz F; Falcone, Alfredo; Tebbutt, Niall C ; Punt, Cornelis J A; Hecht, J Randolph; Souglakos, John; Bokemeyer, Carsten; Van Cutsem, Eric; Saltz, Leonard; de Gramont, Aimery; Sargent, Daniel J |
| 77 | Apr-2017 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. | García-Carbonero, Rocío; van Cutsem, Eric; Rivera, Fernando; Jassem, Jacek; Gore, Ira; Tebbutt, Niall C ; Braiteh, Fadi; Argiles, Guillem; Wainberg, Zev A; Funke, Roel; Anderson, Maria; McCall, Bruce; Stroh, Mark; Wakshull, Eric; Hegde, Priti; Ye, Weilan; Chen, Daniel; Chang, Ilsung; Rhee, Ina; Hurwitz, Herbert |
| 78 | Oct-2016 | MRI rectal cancer in Australia and New Zealand: An audit from the PETACC-6 trial | Gormly, Kirsten L; Coscia, Claudio; Wells, Tim; Tebbutt, Niall C ; Harvey, Jennifer A; Wilson, Kate; Schmoll, Hans-Joachim; Price, Timothy J |
| 79 | Sep-2016 | A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction | Shah, Manish A; Cho, Jae-Yong; Tan, Iain B; Tebbutt, Niall C ; Yen, Chia-Jui; Kang, Alice; Shames, David S; Bu, Lilian; Kang, Yoon-Koo |
| 80 | 10-Aug-2016 | Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II tria | Pavlakis, Nick; Sjoquist, Katrin M; Martin, Andrew J; Tsobanis, Eric; Yip, Sonia; Kang, Yoon-Koo; Bang, Yung-Jue; Alcindor, Thierry; O’Callaghan, Christopher J; Burnell, Margot J; Tebbutt, Niall C ; Rha, Sun Young; Lee, Jeeyun; Cho, Jae-Yong; Lipton, Lara R; Wong, Mark; Strickland, Andrew; Kim, Jin Won; Zalcberg, John R; Simes, John; Goldstein, David |
Loading...
2
0
20
0
false